BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021

MARLBOROUGH, Mass., Feb. 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.127 billion during the fourth...

Related Keywords

United States ,Malaysia ,Taiwan ,Philippines ,Brazil ,China ,Vietnam ,Republic Of ,Boston ,Massachusetts ,Czech Republic ,South Africa ,Colombia ,Indonesia ,Canada ,Russia ,Barcelona ,Comunidad Autonoma De Cataluna ,Spain ,Mexico ,India ,Thailand ,Saudi Arabia ,Chile ,South Korea ,Poland ,Turkey ,America ,Lauren Tengler ,Mike Mahoney ,Kate Haranis ,Boston Scientific Corporation ,American Neuromodulation Society ,Boston Scientific ,Pelvic Health ,Specialty Pharmaceuticals ,Exchange Commission ,Us Centers For Medicare ,Devoro Medical Inc ,Securities Exchange ,Medicaid Services ,Middle East ,Modular Therapy ,Implantable Defibrillator System ,Modular Pacing System ,Spinal Cord Stimulator ,Ambulatory Payment Classification ,Water Vapor Therapy ,Barcelona Clinic Liver Cancer ,Best Places ,Creating Equal Opportunities ,Emerging Markets ,Medical Surgical ,Medical Device ,Foreign Currency Fluctuations ,Recent Acquisitions ,Year Net Sales ,Ended December ,Full Year ,Statement Regarding Forward Looking Statements ,Securities Act ,Securities Exchange Act ,Risk Factors ,Annual Report ,Quarterly Reports ,Months Ended December ,Before Income Taxes ,Common Stockholders ,Mandatory Convertible Preferred Stock ,Financial Accounting Standards Board ,Accounting Standards Codification ,Estimated Annual Effective Tax Rate ,Financial Condition ,Quarterly Report ,